ArticleAnimals : an open access journal from MDPI2026
The Potential of Selective COX-2 Inhibitor Mavacoxib for Extended Analgesia in Sheep Husbandry.
Article in Animals : an open access journal from MDPI, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Routine husbandry procedures in sheep induce significant and prolonged pain and inflammation, which often exceeds the duration of action of current commercially available analgesics. Mavacoxib is a selective cyclooxygenase-2 (COX-2) inhibitor approved for canine osteoarthritis treatment. With a half-life exceeding two weeks in dogs, mavacoxib may represent a candidate for investigating whether extended-duration analgesia can be achieved in sheep and more closely aligned with the duration of post-procedural inflammation and pain. This article examines the physiological and behavioural indicators of sheep pain, the limitations of current analgesic strategies, and the pharmacological rationale for mavacoxib as a candidate for pain management in sheep. Further research into its pharmacokinetics, efficacy, and safety in sheep is essential to improve welfare and overcome practical barriers to analgesia in extensive grazing systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.